- Home
- KRG vs APGE Comparison
KRG vs APGE Comparison
Compare KRG & APGE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | KRG | APGE |
|---|---|---|
| Founded | 1971 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.2B | 4.5B |
| IPO Year | 2004 | 2023 |
Fundamental Metrics
Financial Performance| Metric | KRG | APGE |
|---|---|---|
| Price | $24.95 | $68.17 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 10 |
| Target Price | $25.25 | ★ $103.33 |
| AVG Volume (30 Days) | ★ 1.6M | 1.1M |
| Earning Date | 02-17-2026 | 03-04-2026 |
| Dividend Yield | ★ 4.63% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.64 | N/A |
| Revenue | ★ $856,786,000.00 | N/A |
| Revenue This Year | $1.45 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $39.37 | ★ N/A |
| Revenue Growth | ★ 3.78 | N/A |
| 52 Week Low | $18.52 | $26.20 |
| 52 Week High | $25.19 | $84.56 |
Technical Indicators
Market Signals| Indicator | KRG | APGE |
|---|---|---|
| Relative Strength Index (RSI) | 65.37 | 45.58 |
| Support Level | $24.42 | $60.35 |
| Resistance Level | $25.19 | $66.18 |
| Average True Range (ATR) | 0.51 | 4.25 |
| MACD | 0.13 | 0.02 |
| Stochastic Oscillator | 93.87 | 56.46 |
Price Performance
Historical ComparisonAbout KRG Kite Realty Group Trust
Kite Realty Group Trust specializes in owning, operating, acquiring, developing, and redeveloping high-quality open-air shopping centers and mixed-use assets. The company generates the majority of its revenue from contractual rents and reimbursement payments received from tenants.
About APGE Apogee Therapeutics Inc.
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties.